Clinical Study

Ea2142- Randomized Phase II Study Of Platinum And Etoposide Versus Temozolomide And Capecitabine In Patients With Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Posted Date: May 15, 2019

  • Investigator: Olugbenga Olowokure
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to assess the progression free survival (PFS) of platinum (cisplatin or carboplatin) and etoposide versus the PFS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas


To Be Eligible: Patients Must Be 18 Years Of Age Or Older, Must Have Advanced/Unresectable Gastroenteropancreatic Neuroendocrine Carcinoma, No Prior Systemic Treatment For This Malignancy, Life Expentancy Of At Least 3 Months, Nonpregnant And Nonbreastfeeding.


Gastroenteropancreatic, Gastrointestinal, Cancer, Neuroendocrine, Phase Ii

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.